Gietl Y, Spahn H, Knauf H, Mutschler E
Department of Pharmacology, Johann Wolfgang Goethe-University, Frankfurt/Main, F.R.G.
Eur J Clin Pharmacol. 1990;38(6):587-93. doi: 10.1007/BF00278587.
The pharmacokinetics of S-(+)- and R-(-)-prenylamine was studied in eight healthy volunteers given single and repeated oral doses of the racemic drug. Distinct differences in various pharmacokinetic parameters were found between the S- and R-enantiomer. The maximum plasma concentrations and AUCs of the R-enantiomer exceeded those of the S-enantiomer five-fold; the apparent oral clearance of the S-form was five-times and the renal clearance three-times higher than of the R-form. Acid catalyzed hydrolysis of urine samples released more S-prenylamine, indicating stereoselective glucuronidation of unchanged prenylamine. Plasma protein binding also differed between the two enantiomers, generally with a higher unbound fraction of the S-form, whereas analysis of the bound fractions showed that prenylamine was bound to different plasma proteins with inverse stereoselectivity.
在八名健康志愿者中研究了消旋普尼拉明单次及重复口服给药后 S-(+)-和 R-(-)-普尼拉明的药代动力学。发现 S-和 R-对映体在各种药代动力学参数上存在明显差异。R-对映体的最大血浆浓度和曲线下面积超过 S-对映体五倍;S-型的表观口服清除率是 R-型的五倍,肾清除率是其三倍。尿样的酸催化水解释放出更多的 S-普尼拉明,表明未变化的普尼拉明存在立体选择性葡糖醛酸化。两种对映体之间的血浆蛋白结合也有所不同,通常 S-型的游离分数较高,而结合分数分析表明普尼拉明以相反的立体选择性与不同的血浆蛋白结合。